The latest price target for Celldex Therapeutics (NASDAQ:CLDX) was reported by Barclays on April 20, 2026. The analyst firm set a price target for $45.00 expecting CLDX to rise to within 12 months (a possible 25.59% upside). 20 analyst firms have reported ratings in the last year.

The latest analyst rating for Celldex Therapeutics (NASDAQ:CLDX) was provided by Barclays, and Celldex Therapeutics upgraded their overweight rating.

The last upgrade for Celldex Therapeutics Inc happened on April 20, 2026 when Barclays raised their price target to $45. Barclays previously had an underweight for Celldex Therapeutics Inc.

The last downgrade for Celldex Therapeutics Inc happened on September 27, 2024 when Wolfe Research changed their price target from N/A to N/A for Celldex Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Celldex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Celldex Therapeutics was filed on April 20, 2026 so you should expect the next rating to be made available sometime around April 20, 2027.

While ratings are subjective and will change, the latest Celldex Therapeutics (CLDX) rating was a upgraded with a price target of $24.00 to $45.00. The current price Celldex Therapeutics (CLDX) is trading at is $35.83, which is within the analyst’s predicted range.